EZN-2279 in Patients With ADA-SCID

Related Clinical Trial
A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus cliniMACs HUD for T Cell Depletion Cord Blood Stem Cell Transplantation Study (COBLT) Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency Genetic Basis of Immunodeficiency IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency Sirolimus Prophylaxis for aGVHD in TME SCID Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft Influences on Female Adolescents’ Decisions Regarding Testing for Carrier Status of XSCID Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant EZN-2279 in Patients With ADA-SCID AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID) Patients Treated for SCID (1968-Present) Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China Gene Therapy for ADA-SCID MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim Natural History Study of SCID Disorders Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency SCID Bu/Flu/ATG Study With T Cell Depletion Generalized Neonatal Screening of Severe Combined Immunodeficiencies Neonatal Screening of Severe Combined Immunodeficiencies Gene Therapy for X-linked Severe Combined Immunodeficiency An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Registry Study of Revcovi Treatment in Patients With ADA-SCID Multi-center Clinical Study of Cord Blood Stem Cell Transplantation for SCID

Brief Title

EZN-2279 in Patients With ADA-SCID

Official Title

A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency

Brief Summary

      The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of
      EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated
      with Adagen.

Study Phase

Phase 3

Study Type


Primary Outcome

Number of Patients Detoxified At Each Visit in EZN-2279 Treatment Period

Secondary Outcome

 Safety Summary Data





Study Arms / Comparison Groups

Description:  Patients started on Adagen and crossed over to experimental EZN-2279 treatment after at least a 3 week Lead-in Period on Adagen


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 24, 2014

Completion Date

May 29, 2019

Primary Completion Date

April 10, 2018

Eligibility Criteria

        Inclusion Criteria:

          1. Diagnosis of ADA-deficient combined immunodeficiency

          2. Stable clinical status while receiving therapy with Adagen®. Patients previously
             receiving gene therapy or undergoing hematopoietic stem cell transplantation who still
             require Adagen® treatment are eligible. The dose of Adagen® must be stable for at
             least 6 months prior to study entry.

          3. Have both of the following during the Adagen® Lead-in phase of the study prior to
             EZN-2279 transition:

               1. Trough plasma ADA activity >15 μmol/h/mL while receiving Adagen® and

               2. Total erythrocyte dAXP ≤0.02 μmol/mL from a trough blood sample

          4. Patients or parent/guardian must be capable of understanding the protocol requirements
             and risks and providing written informed assent/consent

        Exclusion Criteria:

          1. Autoimmunity requiring immunosuppressive treatment

          2. Patients with detectable neutralizing anti-Adagen® antibodies at screening evaluation

          3. Severe thrombocytopenia (platelet count <50 x 10^9/L)

          4. Current participation in other therapeutic protocols for ADA-deficient combined

          5. Current or prior participation in another clinical study with an investigational agent
             and/or use of an investigational drug in the 30 days before study entry

          6. Known planned participation in a gene-therapy study for the planned duration of this

          7. Any condition that, in the opinion of the PI, makes the patient unsuitable for the

          8. Inability or unwillingness to administer Adagen® or EZN-2279 on a one-time-per-week

          9. Inability to comply with the study protocol

         10. Female patients who are pregnant or lactating

         11. Female patients who are breast-feeding

         12. Female subjects of childbearing potential who are not using an FDA approved birth
             control method




N/A - N/A

Accepts Healthy Volunteers



Elie Haddad, MD, PhD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Leadiant Biosciences, Inc.

Study Sponsor

Elie Haddad, MD, PhD, Principal Investigator, Université de Montréal

Verification Date

April 2020